• SLC-391 inhibits CT-26 tumor growth by 37% in a 15-day efficacy study whereas PD-1 antibody delayed tumor growth by 27%;
• Increases in the number of NK cells and the ratio of M1/M2-polarized macrophages were evident in the SLC-391 treatment group when compared to vehicle;
• In combination with anti-PD1, SLC-391 significantly prolongs survival, reinforcing the implication of AXL inhibition in immuno-oncology
VANCOUVER, BRITISH COLUMBIA – Oct. 25, 2017 – SignalChem Lifesciences Corporation (“SLC”) announced that it will present a poster detailing the preclinical data for its AXL inhibitor, SLC-391 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held from October 26 – 30, 2017 in Philadelphia, Pennsylvania.
Details of the poster to be presented are as follows:
Title: Activity of the TAM kinase-targeting compound, SLC-391, is mediated by the engagement of the immune system in CT-26 syngeneic mouse model
Abstract Number: 522
Poster Session: PO.B10 – New Molecular Targets
Date and Time: Sunday, October 29; 12:30 – 4:00 PM
Presenter: Anthony Marotta, PhD. SignalChem Lifesciences Corporation
SLC-391 is a selective small molecule inhibitor of AXL and other TAM family kinases (Tyro3 and Mer). Currently, IND-enabling GLP-toxicological studies are underway and are expected to be completed in Q4 2017. With favorable results, SignalChem plans to initiate Phase I clinical trials in Q3 2018.
SLC is a privately held and clinical stage biotechnology company specializing in enabling personalized medicine strategies to improve human health. The company offers bio-reagents (tools and services used for research purposes) to organizations worldwide and leverages the internally developed enzyme technology platform to discover inhibitors of the untapped targets with a view of advancing these therapeutic programs into early clinical development stages. SLC’s current therapeutic development programs are related to hypoxia (cancer), specifically CAIX which is involved in mediating metastasis and AXL tyrosine kinase is involved in perpetuating resistance to standard chemo- and radiation therapy. SLC has established a strategic corporate alliance with Welichem Biotech Inc. to support the clinical development of its first program SLC-0111, a CAIX inhibitor for the treatment of metastatic cancer. A Phase 1B study evaluating SLC-0111 with gemcitabine in pancreatic cancer is expected to commence in Q1 2018. GLP toxicological studies for SLC’s second program, Axl inhibitor SLC-391, are currently underway with results to be expected in Q4, 2017. SLC is actively seeking opportunities for a co-development partnership for the AXL program.
Forward-Looking Statements and Information
This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.
Dr. Anthony Marotta, PhD
Business and Clinical Advisor
SignalChem Lifesciences Corporation